O Mikhail | PubMed Health

PubMed1999

Technology evolution: the technology spectrum and its application to orthopedic technologies.

The evolution of clinical technologies presents potential adopters with considerations in planning for clinical program development that include the stage and the rate of a technology's evolution. This paper presents a conceptual framework for these considerations and applies the framework to orthopedic technologies. Eight orthopedic surgeons were asked to assess 14 orthopedic technologies and position each of them along a spectrum of research, clinical, and adopted technologies. The distribution of responses for each technology-year combination is presented, and estimates of central tendency, dispersion, and variances provide measures of the change in the distribution of responses over time for each technology and the change in the degree of rater consensus over time for each technology. While orthopedic trauma was chosen to illustrate the technology spectrum model, the model and assessment methodology is applicable to other medical specialties as well. Adoption of this framework in a hospital setting should enable more systematic and effective clinical program development.

Diffusion of Innovation↗

PubMed1994

The cost of congenital heart disease in children and adults. A model for multicenter assessment of price and practice variation.

OBJECTIVE: To assess the cost of congenital heart disease (CHD) and to assess whether practice pattern or price was more responsible for variation. RESEARCH DESIGN AND SETTING: Data were collected from Charleston, NC; Columbus, Ohio; Detroit, Mich; Houston, Tex; Los Angeles, Calif; and New York, NY. The CHD was first classified as to physiologic characteristics and severity. For each type of CHD, the number of clinic visits, hospitalizations, and years of medication use were estimated. RESULTS: On the basis of actual charges, the "prices" were calculated as follows, in 1992 dollars: for patients from birth to 21 years: benign disease (19% of patients), $3940; acyanotic disease (45%), $49,730; cyanotic disease (36%), $102,084; and average for all CHD categories, $59,877; for patients 22 to 40 years of age (of whom 24% had resolved defects or were dead): benign disease (19%), $3470; acyanotic disease (52%), $12,981; cyanotic disease (29%), $39,187; and average for all CHD, $18,773. The cost for the group from birth to 21 years varied from $47,500 to $73,600, accounting for 55% by practice (number of echocardiograms and cardiac catheterizations) and 45% by price, although mortality was similar. CONCLUSIONS: The treatment of CHD is comparatively inexpensive, especially in adult survivors. The variation in both practice and price bears further study, with comparison to determine the most cost-effective strategies for treating these patients.

Adolescent↗